Elixir’s drilling contract paves way for resource conversion


Published 01-AUG-2019 09:49 A.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Elixir Energy Ltd (ASX:EXR) informed the market on Thursday that management had signed a binding drilling services contract with Mongolian company Erdenedrilling LLC.

This is another step in the company’s progression to commencement of drilling at the group’s Nomgon IX coal bed methane (CBM) production sharing contract (PSC). Elixir has a 100% interest in the Nomgon IX CBM PSC, located proximate to the Chinese border in Mongolia’s South Gobi region.

The PSC was entered into with the Mongolian Government in September 2018 and has a minimum 10 year exploration period and a thirty year (extendable) production period.

Today’s contract following Elixir’s July 18 announcement that Erdenedrilling was its preferred drilling contractor.

Prospective CBM unrisked resource of 40.1 Tcf

Elixir has snared a massive independently certified recoverable prospective coal bed methane (CBM) resource of 7.6 trillion cubic feet (risked “best” or mid case) and 40.1 Tcf (unrisked) in southern Mongolia, right on the border of China.

This gas resource sits within a giant seven million acre (30,000km2) PSC - the Nongom IX CBM PSC.

Elixir has procured various required government approvals in recent months. The last major approval granted was in connection with a Detailed Environmental Impact Assessment (DEIA), the receipt of which on July 11, 2019 now allows field work to commence.

Ongoing geological work has resulted in the identification of a number of leads where coal is known to be present within the CBM depth window.

These leads are now the focus of a targeted seismic program which has been transformed from one of regional exploration into one of de-risking specific leads.

First well expected September/October

The contract commits Elixir to a minimum of two fully tested coreholes with the option for another well. These will be the first CBM wells in Mongolia to be tested to international best practice gas industry standards

Management expect to commence of drilling operations post the acquisition of initial seismic data and selected of well locations. It estimates the first well will be spudded in or around late September/early October.

Erdenedrilling has sub-contracted Arizona based Coal Gas Techology Co (CGT) to supply equipment and technical services in connection with gas content testing. CGT has more than 30 years of experience in providing such services to the CBM industry across North America, Australia, China and other countries.

Elixir will directly source permeability testing services from Australia and will make a separate announcement on this shortly.

Discussing the importance of the upcoming drilling campaign in terms of converting prospective resources into contingent resources Elixir’s managing director Neil Young said “Our upcoming core-hole program is on track to supply us with the key data we need to start to convert part of the massive prospective resources independently confirmed in our PSC into contingent resources.

‘’Quite simply, we aim to book Mongolia’s first gas discovery within less than six months.”

Shares trading at 50% premium to placement price

During the quarter the Elixir made a placement of 97,440,807 shares at a price of 3.6 cents, raising approximately $3.6 million before costs.

The company is well placed financially to fund upcoming exploration as it was debt free as at June 30, 2019 and had cash reserves of approximately $4.3 million.

Investors who participated in the capital raising are already sitting pretty with the company’s share price of 5.4 cents implying a gain of 50% relative to the placement price.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free